白血球アフェレーシス市場 - 世界の産業規模、シェア、動向、機会、予測：タイプ別、用途別、エンドユーザー別、地域別、競合別、2019-2029年

白血球アフェレーシスの世界市場規模は2023年に7,652万米ドルとなり、2029年までの予測期間のCAGRは5.25%で着実な成長が予測されています。

白血球アフェレーシスの世界市場は、ヘルスケア技術の進歩、血液疾患の有病率の増加、個別化治療に対する需要の高まりなどを背景に、近年大きな成長を遂げています。血液から白血球を分離する医療処置である白血球アフェレーシスは、さまざまな治療用途で重要な役割を果たしており、血液学および腫瘍学の分野で重要な役割を担っています。世界の白血球アフェレーシス市場は、幅広い技術、製品、アプリケーションを包含しており、その多様でダイナミックな性質に寄与しています。白血球アフェレーシス法は、免疫系に不可欠な白血球を分離・採取するために使用されます。市場はタイプ、用途、エンドユーザー、地域によって区分されます。

市場促進要因

血液疾患および血液がんの発生率の増加

臨床研究と医薬品開発への注目の高まり

主な市場課題

高い初期費用と限られた償還

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（白血球アフェレーシスデバイス、アフェレーシスデバイス、白血球アフェレーシスカラム、細胞分離装置、白血球除去フィルター、白血球アフェレーシス消耗品）
  • 用途別（調査用途、治療用途）
  • エンドユーザー別（血液成分供給業者・血液センター、学術研究機関、製薬・バイオテクノロジー企業、病院・輸血センター）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 北米の白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第7章 欧州の白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第8章 アジア太平洋地域の白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第9章 南米の白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第10章 中東・アフリカの白血球アフェレーシス市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 競合情勢

• Asahi Kasei Medical Co. Ltd
• Haemonetics Corporation
• TERUMO BCT INC.
• STEMCELL Technologies Canada Inc.
• Fresenius SE & Co. KGaA
• B. Braun SE
• Caltag Medsystems Limited
• Precision Medicine Group, LLC
• Lmb Technologie GmbH
• Grifols, S.A
• Kaneka Pharma Europe NV

第14章 戦略的提言

第15章 調査会社について・免責事項

Global Leukapheresis Market was valued at USD 76.52 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. The Global Leukapheresis Market has been experiencing significant growth in recent years, driven by advancements in healthcare technology, increasing prevalence of blood disorders, and a rising demand for personalized therapies. Leukapheresis, a medical procedure that involves separating white blood cells from blood, plays a crucial role in various therapeutic applications, making it a key player in the field of hematology and oncology. The global leukapheresis market encompasses a wide range of technologies, products, and applications, contributing to its diverse and dynamic nature. Leukapheresis procedures are employed for the isolation and collection of leukocytes, primarily white blood cells, which are essential components of the immune system. The market is segmented based on product types, applications, end-users, and regions.

Key Market Drivers

Rising Incidence of Blood Disorders and Hematologic Cancers

In recent years, the global healthcare landscape has witnessed a notable surge in the incidence of blood disorders and hematologic cancers. This alarming trend has led to an increased demand for advanced therapeutic solutions, and one such technology gaining prominence is leukapheresis. Leukapheresis, a medical procedure that involves the separation and removal of white blood cells (leukocytes) from the blood, has become a critical component in the treatment of various hematologic conditions. As the prevalence of these disorders continues to rise, the global leukapheresis market is experiencing significant growth. Blood disorders and hematologic cancers encompass a broad spectrum of conditions, including leukemia, lymphoma, myeloma, and various anemias. The incidence of these disorders has been steadily increasing, placing a substantial burden on healthcare systems worldwide. Factors such as aging populations, exposure to environmental carcinogens, and genetic predispositions contribute to the rising prevalence of these diseases.

Leukapheresis is used to control elevated white blood cell counts in conditions like leukemia, preventing complications such as organ damage and clotting. For patients undergoing stem cell transplantation, leukapheresis is employed to collect healthy hematopoietic stem cells, which are essential for the restoration of the bone marrow and immune system. In certain autoimmune disorders, leukapheresis helps modulate the immune response by removing pathogenic white blood cells responsible for the autoimmune attack. Leukapheresis is also utilized in therapeutic plasma exchange, where plasma containing harmful antibodies or toxins is separated and replaced with a suitable substitute.

Growing Focus on Clinical Research and Drug Development

In recent years, the field of clinical research and drug development has experienced a significant surge in attention and investment. This heightened focus is primarily driven by the increasing prevalence of complex diseases and the need for innovative therapies. Within this landscape, the global leukapheresis market has emerged as a crucial player, providing essential tools and technologies to advance research and drug discovery processes. Immunotherapy has emerged as a revolutionary approach to treating various diseases by harnessing the body's immune system to target and eliminate abnormal cells. Leukapheresis is a crucial step in the development of immunotherapies, as it allows researchers to isolate immune cells, such as T cells, for genetic modification or activation before reintroducing them into the patient's body. The success of immunotherapeutic approaches, particularly in oncology, has propelled the demand for leukapheresis technologies.

The growing trend towards precision medicine and personalized therapies further underscores the importance of leukapheresis in clinical research. By isolating specific cell types from individual patients, researchers can tailor treatment strategies to the unique characteristics of each patient, enhancing treatment efficacy and minimizing adverse effects. This patient-centric approach is reshaping the drug development landscape and driving the adoption of leukapheresis technologies. Advancements in leukapheresis technologies have significantly enhanced their efficiency, precision, and scalability. Automated systems closed processing systems, and advanced separation techniques have streamlined the leukapheresis process, making it more accessible and reliable for large-scale clinical trials. These technological improvements are catalyzing the growth of the global leukapheresis market and empowering researchers to conduct more sophisticated studies.

Key Market Challenges

High Initial Costs and Limited Reimbursement

The significant challenges confronting the global leukapheresis market is the high initial costs associated with the technology and equipment required for the procedure. The implementation of advanced leukapheresis technologies, including automated systems and specialized devices, demands substantial financial investments. This poses a barrier for healthcare facilities, especially in developing regions, limiting their ability to adopt and integrate these technologies. The costs associated with leukapheresis equipment, disposable kits, and maintenance contribute to the financial burden on healthcare providers. Moreover, the need for skilled personnel to operate and manage these sophisticated systems adds to the overall expenses. As a result, smaller healthcare facilities and those with limited budgets may find it challenging to embrace the latest leukapheresis technologies, hindering the market's growth potential. In addition to high initial costs, the limited reimbursement options for leukapheresis procedures pose a substantial challenge for both healthcare providers and patients. Reimbursement policies vary across regions, and in some cases, the reimbursement rates may not adequately cover the costs associated with leukapheresis. This creates a financial strain on healthcare facilities and may deter them from offering these procedures. The lack of standardized reimbursement models for leukapheresis can lead to disparities in access to this critical medical intervention. Patients may face difficulties in obtaining insurance coverage for leukapheresis treatments, limiting their ability to benefit from the procedure. This not only affects the overall adoption of leukapheresis but also exacerbates healthcare inequalities, as access to advanced medical interventions becomes contingent on financial means.

Key Market Trends

Technological Advancements

In recent years, the field of healthcare has witnessed an unprecedented surge in technological advancements, leading to groundbreaking innovations and transformative changes. One such area that has benefited immensely from these advancements is the Global Leukapheresis Market. Leukapheresis, a medical procedure involving the separation and collection of white blood cells (leukocytes) from the blood, plays a crucial role in various therapeutic and diagnostic applications. The integration of cutting-edge technologies has not only enhanced the efficiency and precision of leukapheresis procedures but has also opened up new avenues for therapeutic advancements. The incorporation of automation and robotics has significantly streamlined the leukapheresis process. Automated systems can perform procedures with high precision, reducing the risk of manual errors. This not only ensures a higher quality of collected cells but also enhances the overall efficiency of the procedure, allowing healthcare professionals to focus on patient care.

Technological advancements in cell separation techniques have revolutionized the isolation of specific cell populations during leukapheresis. Novel methods, such as microfluidics and advanced filtration systems, enable a more targeted and efficient collection of white blood cells. This level of precision is crucial in applications like stem cell transplantation and immunotherapy. Artificial intelligence has found its way into leukapheresis technologies, offering predictive analytics and real-time monitoring capabilities. AI algorithms can analyze data during the procedure, optimizing parameters for cell collection and minimizing potential side effects. This not only improves the safety profile of leukapheresis but also enhances its efficacy. Apheresis devices, the cornerstone of leukapheresis, have evolved significantly. Next-generation devices offer improved scalability, allowing for increased throughput and faster procedures. Moreover, these devices often come equipped with user-friendly interfaces and connectivity features, facilitating seamless integration into healthcare systems. Technological advancements in cell processing have led to the development of closed-system platforms, reducing the risk of contamination and ensuring the sterility of collected cells. Additionally, these advancements enable the manipulation and modification of collected cells for therapeutic purposes, contributing to the expanding field of personalized medicine.

Segmental Insights

Type Insights

Based on the category of type, Leukapheresis Devices emerged as the dominant segment in the global market for Leukapheresis in 2023. Leukapheresis devices have seen substantial technological advancements, enabling more precise and efficient cell separation. Innovations such as continuous flow centrifugation and closed-system processing have enhanced the safety and effectiveness of the leukapheresis procedure. The increasing prevalence of blood-related disorders, such as leukemia and lymphoma, has led to a surge in the demand for leukapheresis procedures. Leukapheresis devices have become indispensable in the collection of white blood cells for subsequent therapeutic applications, such as stem cell transplantation. The rise of cell-based therapies, including chimeric antigen receptor T-cell (CAR-T) therapy, has further propelled the demand for leukapheresis devices. These devices play a pivotal role in collecting and isolating the patient's immune cells for the development of personalized and targeted therapies.

Regional Insights

North America emerged as the dominant region in the global Leukapheresis market in 2023, holding the largest market share in terms of value. North America boasts a robust healthcare infrastructure and is at the forefront of technological advancements in medical procedures. The region has witnessed continuous innovation in leukapheresis technologies, leading to improved efficiency, safety, and patient outcomes. The adoption of automated systems and advanced cell separation techniques has positioned North American companies as leaders in the global market. The prevalence of blood disorders, including leukemia, has been on the rise globally. North America, with a large and aging population, has experienced a growing demand for therapeutic interventions such as leukapheresis. The region's proactive approach to healthcare, coupled with a high awareness of blood-related diseases, has fueled the demand for leukapheresis procedures.

Key Market Players

Asahi Kasei Medical Co. Ltd

Haemonetics Corporation

TERUMO BCT INC.

STEMCELL Technologies Canada Inc.

Fresenius SE & Co. KGaA

B. Braun SE

Caltag Medsystems Limited

Precision Medicine Group, LLC

Lmb Technologie GmbH

Grifols, S.A

Kaneka Pharma Europe NV

Report Scope:

In this report, the Global Leukapheresis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Leukapheresis Market, By Type:

Leukapheresis Devices Apheresis Devices Leukapheresis Columns Cell Separators Leukoreduction Filters Leukapheresis Disposables

Leukapheresis Market, By Application:

Research Applications Therapeutic Applications

Leukapheresis Market, By End User:

Blood Component Providers and Blood Centers Academic and Research Institutes Pharmaceutical and Biotechnology Companies Hospitals and Transfusion Centers

Leukapheresis Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Leukapheresis Market.

Available Customizations:

Global Leukapheresis market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Leukapheresis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Leukapheresis Devices, Apheresis Devices, Leukapheresis Columns, Cell Separators, Leukoreduction Filters, Leukapheresis Disposables)
  • 5.2.2. By Application (Research Applications, Therapeutic Applications)
  • 5.2.3. By End User (Blood Component Providers and Blood Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Transfusion Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Leukapheresis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
    • 6.2.4.1. United States Leukapheresis Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
      • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
      • 6.2.4.1.2.1. By Type
      • 6.2.4.1.2.2. By Application
      • 6.2.4.1.2.3. By End User
    • 6.2.4.2. Canada Leukapheresis Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
      • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
      • 6.2.4.2.2.1. By Type
      • 6.2.4.2.2.2. By Application
      • 6.2.4.2.2.3. By End User
    • 6.2.4.3. Mexico Leukapheresis Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
      • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
      • 6.2.4.3.2.1. By Type
      • 6.2.4.3.2.2. By Application
      • 6.2.4.3.2.3. By End User

7. Europe Leukapheresis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
    • 7.2.4.1. France Leukapheresis Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Type
      • 7.2.4.1.2.2. By Application
      • 7.2.4.1.2.3. By End User
    • 7.2.4.2. Germany Leukapheresis Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Type
      • 7.2.4.2.2.2. By Application
      • 7.2.4.2.2.3. By End User
    • 7.2.4.3. United Kingdom Leukapheresis Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Type
      • 7.2.4.3.2.2. By Application
      • 7.2.4.3.2.3. By End User
    • 7.2.4.4. Italy Leukapheresis Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Type
      • 7.2.4.4.2.2. By Application
      • 7.2.4.4.2.3. By End User
    • 7.2.4.5. Spain Leukapheresis Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Type
      • 7.2.4.5.2.2. By Application
      • 7.2.4.5.2.3. By End User

8. Asia Pacific Leukapheresis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
    • 8.2.4.1. China Leukapheresis Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
      • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
      • 8.2.4.1.2.1. By Type
      • 8.2.4.1.2.2. By Application
      • 8.2.4.1.2.3. By End User
    • 8.2.4.2. India Leukapheresis Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
      • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
      • 8.2.4.2.2.1. By Type
      • 8.2.4.2.2.2. By Application
      • 8.2.4.2.2.3. By End User
    • 8.2.4.3. South Korea Leukapheresis Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
      • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
      • 8.2.4.3.2.1. By Type
      • 8.2.4.3.2.2. By Application
      • 8.2.4.3.2.3. By End User
    • 8.2.4.4. Japan Leukapheresis Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
      • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
      • 8.2.4.4.2.1. By Type
      • 8.2.4.4.2.2. By Application
      • 8.2.4.4.2.3. By End User
    • 8.2.4.5. Australia Leukapheresis Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
      • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
      • 8.2.4.5.2.1. By Type
      • 8.2.4.5.2.2. By Application
      • 8.2.4.5.2.3. By End User

9. South America Leukapheresis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Leukapheresis Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Type
      • 9.2.4.1.2.2. By Application
      • 9.2.4.1.2.3. By End User
    • 9.2.4.2. Argentina Leukapheresis Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Type
      • 9.2.4.2.2.2. By Application
      • 9.2.4.2.2.3. By End User
    • 9.2.4.3. Colombia Leukapheresis Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Type
      • 9.2.4.3.2.2. By Application
      • 9.2.4.3.2.3. By End User

10. Middle East & Africa Leukapheresis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Leukapheresis Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
      • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
      • 10.2.4.1.2.1. By Type
      • 10.2.4.1.2.2. By Application
      • 10.2.4.1.2.3. By End User
    • 10.2.4.2. Saudi Arabia Leukapheresis Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
      • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
      • 10.2.4.2.2.1. By Type
      • 10.2.4.2.2.2. By Application
      • 10.2.4.2.2.3. By End User
    • 10.2.4.3. UAE Leukapheresis Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
      • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
      • 10.2.4.3.2.1. By Type
      • 10.2.4.3.2.2. By Application
      • 10.2.4.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Asahi Kasei Medical Co. Ltd
  • 13.1.1. Business Overview
  • 13.1.2. Product & Service Offerings
  • 13.1.3. Financials (If Listed)
  • 13.1.4. Recent Developments
  • 13.1.5. Key Personnel
  • 13.1.6. SWOT Analysis
• 13.2. Haemonetics Corporation
• 13.3. TERUMO BCT INC.
• 13.4. STEMCELL Technologies Canada Inc.
• 13.5. Fresenius SE & Co. KGaA
• 13.6. B. Braun SE
• 13.7. Caltag Medsystems Limited
• 13.8. Precision Medicine Group, LLC
• 13.9. Lmb Technologie GmbH
• 13.10. Grifols, S.A
• 13.11. Kaneka Pharma Europe NV

14. Strategic Recommendations

15. About us & Disclaimer